by Biospring | Apr 26, 2022 | Analytics, Decision Making, Investing, Moneyball, Portfolio Management, Returns
Drew Pearson, Biospring’s Chief Operating Officer, recently led a discussion for Limited Partners on best practices in Portfolio Management. We’re pleased to share a recap of the discussion below. “When I think about private equity as an industry,...
by Biospring | Apr 26, 2022 | Advanced Therapy, Cell Therapy, CGT, Gene Therapy, Geoffrey Glass, IPSC, Kiniciti, NCardia
In November 2021, we were pleased to announce our investment in Kiniciti, a Cell & Gene Therapy (“CGT”) aggregator. Later in November, Kiniciti announced its first strategic partnership with Ncardia, a leader in developing stem cell-based solutions for...
by Biospring | Apr 26, 2022 | Cell and Gene Therapy, Cell Therapy, CGT, Gene Therapy, Kiniciti
We’re pleased to announce our investment in Kiniciti, a Cell and Gene Therapy (“CGT”) aggregator. We’ve had the pleasure of working with Kiniciti over the past year to identify opportunities in the cell and gene therapy market. Biospring’s...
by Biospring | Apr 26, 2022 | Artificial Intelligence, Data, Drug Discovery, Health Care, John Baldoni, Pharma
We recently hosted a discussion with Dr. John Baldoni, one of Biospring’s Operational Experts. He is the Co-Founder and Chief Scientific Officer of SaponiQx, a recently formed vaccine discovery and development company. He’s also the CEO of the Atom...
by Biospring | Apr 26, 2022 | Health Care, Ixlayer, Labs, Precision Health, Telehealth
We are excited to be investors in ixlayer, a company that’s reinventing the health ecosystem by empowering every individual to manage their health testing at home. ixlayer’s technology infrastructure and software is leveraged by large enterprises to enable...
